BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, February 10, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 31, 2001
View Archived Issues
FDA approves insulin analogue for pump therapy
Read More
Positive phase I/II AlloMune results for end-stage lymphoma
Read More
Kyowa Hakko develops new antibody technology
Read More
GeneProt delivers potential protein candidates to Novartis
Read More
Preparation and use of new thienopyrimidinediones discovered at AstraZeneca
Read More
Uriach researchers identify selective COX-2 inhibitors with antiinflammatory activity
Read More
Schering discloses new series of antiangiogenic agents
Read More
Novel epothilone derivatives from Schering act as microtubule-stabilizing agents
Read More
Vancomycin analogues with activity against enterococci and staphylococci
Read More
Inhibitors of shikamate pathway enzyme under development at Arrow as novel antibiotics
Read More
Design and preclinical evaluation of a new class of bacterial peptide deformylase inhibitors
Read More
Oxapenem beta-lactamase inhibitors reported at ICAAC to extend spectrum of cephalosporins
Read More
MitoKor and Pfizer extend mitochondrial dysfunction collaboration
Read More
ISV-401 enters phase II trials for bacterial conjunctivitis
Read More
Schering and MorphoSys enter therapeutic and diagnostic R&D agreement
Read More
AHP and Elan form sleep disorder alliance
Read More
Preliminary preclinical data demonstrate tumor vascular targeting efficacy of OXI-4503
Read More
Celera and Syrrx enter structural proteomics collaboration
Read More
